Prof. Dr. Detlev Riesner
Professor Dr. Riesner held the chair of Biophysics at Heinrich Heine University in Düsseldorf from 1980 to 2006, was dean of the Science Faculty and prorector of research. Since his retirement in 2006, he was member of the board of trustees of Heinrich Heine University until 2017. During his academic career Professor Dr. Riesner worked as a research assistant at Princeton University and as a visiting professor at the University of California, San Francisco and Academia Sinica (China). Professor Dr. Riesner is a co-founder of Qiagen N.V., member of the Supervisory Board and held the position as Chairman of the Supervisory Board from 1999 to 2014. He was also a member of the Supervisory Boards of NewLab Bioquality AG, Erkrath, Drevo AG, Cologne, Alantos AG, Heidelberg and AC Immune, Lausanne. Furthermore, Professor Riesner was a member of the Scientific Advisory Board of the Friedrich-Löffler Institute, Isle of Riems and PrioNet and APRI, both in Canada. He received awards from the Federal Government, from the State of NRW and the Max Planck Society. Prof. Dr. Riesner works with Priavoid as a business angel, partner and mentor.
Prof. Dr. Stanley Prusiner
Professor Dr. Stanley Ben Prusiner is an American neurologist and biochemist. He is the director of the Institute for Neurodegenerative Diseases at the University of California, San Francisco (UCSF). Prusiner discovered prions, a class of infectious self-reproducing pathogens composed of protein. He won the Nobel Prize in Physiology or Medicine in 1997 for his discovery of prions that cause bovine spongiform encephalopathy ("mad cow disease") and its human equivalent, Creutzfeldt–Jakob disease. In 1982, he coined the term prion, derived from the words “proteinaceous” and “infection,” to refer to a previously undescribed form of infection due to protein misfolding.
Prof. Dr. Dieter Willbold
Full Professor for “Physical Biology” at the Heinrich Heine University in Düsseldorf and Director at the Institute of Complex Systems, Structural Biochemistry (IBI-7) at the Forschungszentrum Jülich, is biochemist, biophysicist, structural biologist, and a long-standing expert in the field of AD. He developed the innovative treatment strategy to target severe neurodegenerative disorders and is coinventor of multiple novel drug candidates. Prof. Dr. Willbold has profound expertise in the technology platform applied to identify and optimize D-peptide based drug candidates for the treatment of neurological disorders with high medical needs.